NervGen Pharma Corp. (NGEN) - Latest Market Data

Price & Market Data

Price: $2.16

Daily Change: +$0.0794 / 3.68%

Daily Range: $1.98 - $2.28

Market Cap: $175,071,392

Daily Volume: 5,786,139

Performance Metrics

1 Week: -42.22%

1 Month: -46.94%

3 Months: -51.96%

6 Months: -66.98%

1 Year: -66.98%

YTD: -66.98%

About NervGen Pharma Corp. (NGEN)

An extensive look into NervGen Pharma Corp. (NGEN). Current price: 2.16, daily change: +$0.0794 / 3.68%. Market cap: 175,071,392. Performance from YTD to 1-year.

Company Details

Employees: 8

Sector: Health technology

Industry: Pharmaceuticals: major

Country: Canada

Details

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Selected stocks

Idea Acquisition Corp. (IACO)

Janus Living, Inc. (JAN)

Hemab Therapeutics Holdings, Inc. (COAG)

JATT II Acquisition Corp (JATT)

Green Circle Decarbonize Technology Limited (GCDT)